TY - JOUR
T1 - Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer
AU - Colombo, Nicoletta
AU - Huang, Gloria
AU - Scambia, Giovanni
AU - Chalas, Eva
AU - Pignata, Sandro
AU - Fiorica, James
AU - Vanle, Linda
AU - Ghamande, Sharad A
AU - González-Santiago, Santiago
AU - Bover, Isabel
AU - Suárez, Begoña Graña
AU - Green, Andrew
AU - Huot-Marchand, Philippe
AU - Bourhis, Yann
AU - Karve, Sudeep
AU - Blakeley, Christopher
N1 - Funding Information:
We thank the following ENGAGE study co-investigators who contributed to patient recruitment and data collection: Italy: Laura Cortesi (University Hospital Azienda Ospedaliero-Universitaria Policlinico di Modena), Sabino De Placido (Università Federico II di Napoli), Serafina Mammoliti (IRCCS Hospital San Martino), Franco Odicino (University of Brescia), and Paolo Zola (University of Turin); Spain: José Ángel Arranz Arija (Hospital Gregorio Marañón), Alfonso Yubero Esteban (Hospital Clínico Universitario Lozano Blesa), Tomás Pascual (Hospital La Princesa), and Andrés Redondo (Hospital Universitario La Paz); United States: John Chan (California Pacific Medical Center Research Institute/Palo Alto Medical Foundation), Paul DiSilvestro (Women and Infants Hospital), Veena John (Monter Cancer Center, NS-LIJHS), Donna McNamara (Hackensack University Medical Center), and Susan Zweizig (University of Massachusetts Memorial Medical Center). We thank Nazneen Rahman (Institute of Cancer Research, London), who contributed to the study design and data review; Ilian Tchakov and Jerzy Tyczynski (formerly AstraZeneca), who contributed to the study design; Alvin Milner (AstraZeneca), who contributed to data review and manuscript preparation; and Kamil Jedynski, Yasmina Tazir, and Hilary Bagguley (AstraZeneca), who contributed to study management and execution. Writing assistance was provided by Gillian Keating from Mudskipper Business Limited, funded by AstraZeneca. Current affiliation for Gloria Huang is Yale School of Medicine and Yale Cancer Center, New Haven, CT, and current affiliation for Sudeep Karve is AbbVie Inc, North Chicago, IL.
Publisher Copyright:
© 2018 by American Society of Clinical Oncology
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Purpose There is a growing demand for BRCA1/2 mutation (BRCAm) testing in patients with ovarian cancer; however, the limited number of genetic counselors presents a potential barrier. To facilitate more widespread BRCAm testing in ovarian cancer, pretest counseling by the oncology team could shorten testing turnaround times and ease the pressure on genetic counselors. Patients and Methods The prospective, observational Evaluating a Streamlined Onco-genetic BRCA Testing and Counseling Model Among Patients With Ovarian Cancer (ENGAGE) study evaluated a streamlined, oncologist-led BRCAm testing pathway. The analysis population comprised 700 patients with ovarian cancer at 26 sites in the United States, Italy, and Spain. The primary objectives were to assess turnaround time and, using questionnaires, to evaluate stakeholder satisfaction (patients, oncologists, and geneticists or genetic counselors) with the oncologist-led BRCAm testing pathway. Results The median overall turnaround time was 9.1 weeks (range, 0.9 to 37.1 weeks), with median turnaround times in the United States, Italy, and Spain of 4.1 weeks (range, 0.9 to 37.1 weeks), 20.4 weeks (range, 2.9 to 35.4 weeks), and 12.0 weeks (range, 2.0 to 36.7 weeks), respectively. Patient satisfaction with the oncologist-led BRCAm testing pathway was high, with . 99% of patients expressing satisfaction with pre- and post-BRCAm test counseling. Oncologist satisfaction with the BRCAm testing pathway was also high, with . 80% agreeing that the process for performing BRCAm testing worked well and that counseling patients on BRCAm testing was an efficient use of their time. Oncologists expressed higher levels of satisfaction with the BRCAm testing pathway than did geneticists or genetic counselors. Conclusion The results of the ENGAGE study demonstrate that an oncologist-led BRCAm testing process is feasible in ovarian cancer. Development of local BRCAm testing guidelines similar to the one used in this study could allow faster treatment decisions and better use of resources in the management of patients with ovarian cancer.
AB - Purpose There is a growing demand for BRCA1/2 mutation (BRCAm) testing in patients with ovarian cancer; however, the limited number of genetic counselors presents a potential barrier. To facilitate more widespread BRCAm testing in ovarian cancer, pretest counseling by the oncology team could shorten testing turnaround times and ease the pressure on genetic counselors. Patients and Methods The prospective, observational Evaluating a Streamlined Onco-genetic BRCA Testing and Counseling Model Among Patients With Ovarian Cancer (ENGAGE) study evaluated a streamlined, oncologist-led BRCAm testing pathway. The analysis population comprised 700 patients with ovarian cancer at 26 sites in the United States, Italy, and Spain. The primary objectives were to assess turnaround time and, using questionnaires, to evaluate stakeholder satisfaction (patients, oncologists, and geneticists or genetic counselors) with the oncologist-led BRCAm testing pathway. Results The median overall turnaround time was 9.1 weeks (range, 0.9 to 37.1 weeks), with median turnaround times in the United States, Italy, and Spain of 4.1 weeks (range, 0.9 to 37.1 weeks), 20.4 weeks (range, 2.9 to 35.4 weeks), and 12.0 weeks (range, 2.0 to 36.7 weeks), respectively. Patient satisfaction with the oncologist-led BRCAm testing pathway was high, with . 99% of patients expressing satisfaction with pre- and post-BRCAm test counseling. Oncologist satisfaction with the BRCAm testing pathway was also high, with . 80% agreeing that the process for performing BRCAm testing worked well and that counseling patients on BRCAm testing was an efficient use of their time. Oncologists expressed higher levels of satisfaction with the BRCAm testing pathway than did geneticists or genetic counselors. Conclusion The results of the ENGAGE study demonstrate that an oncologist-led BRCAm testing process is feasible in ovarian cancer. Development of local BRCAm testing guidelines similar to the one used in this study could allow faster treatment decisions and better use of resources in the management of patients with ovarian cancer.
UR - http://www.scopus.com/inward/record.url?scp=85046007455&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046007455&partnerID=8YFLogxK
U2 - 10.1200/JCO.2017.76.2781
DO - 10.1200/JCO.2017.76.2781
M3 - Article
C2 - 29558274
AN - SCOPUS:85046007455
SN - 0732-183X
VL - 36
SP - 1300
EP - 1307
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 13
ER -
